Dr. Eugene Huang

Dr. Eugene Huang

Hi, I am Dr. Huang. Please click below to start a visit with me.

START A VISIT

Address

6605 Nancy Ridge Drive San Diego, CA 92121

Phone

(858) 900-2766

Social Media Handles

Telemedicine

24x7

States Supported

CA

Working Hours

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday

8:00AM-5:00PM

8:00AM-5:00PM

8:00AM-5:00PM

8:00AM-5:00PM

8:00AM-5:00PM

8:00AM-5:00PM

8:00AM-5:00PM

About Dr. Eugene Huang

Eugene Huang MD, PhD is a board certified dermatologist from Poway Dermatology in San Diego, CA.


Conditions Treated

All medical dermatology diseases, including acne, rosacea, contact dermatitis, skin discoloration, cellulitis, rashes, HSV, herpes, warts, ulcers, skin lesions, malignant neoplasms of the skin, nail issues, hair loss, skin aging, cold sores, sun damage or actinic keratoses, epidermal cysts, eczema, psoriasis, seborrheic keratosis or benign skin tumors, dandruff or seborrheic dermatitis or cradle cap, folliculitis, hives or urticaria, atopic dermatitis, tinea or tinea versicolor, fungal infections, cosmetic procedure follow-up, surgical procedure follow-up, inflammatory skin diseases, parasitic infections, such as scabies or head lice.


Online Visits Available In

California: Accepting Established Patients Only


Qualifications and Education

Education: 1993 B.A. in Chemistry (Magna Cum Laude) Carleton College, Northfield, MN 1995-2005 M.D., Ph.D in Medicine, Immunology University of Washington, Seattle, WA. 2005-2006 Internship University of California San Diego, La Jolla, CA 2006-2009 Dermatology Residency University of California San Diego, La Jolla, CA Training: 2010 Good Clinical Practice Training CITI Collaborative Institutional Training Initiative Professional Employment: 2009– Present Therapeutics Clinical Research, San Diego, California Clinical Investigator 2009 – Present Skin Epibiotics, San Diego, CA Chief Medical Officer 2009 – Present University of California Medical Center, San Diego, CA Associate Physician 2009 – Present Director of Teledermatology, VA Medical Center, San Diego, CA Staff Physician 2006 – 2009 University of California Medical Center, San Diego, CA Resident in Dermatology 2005 – 2006 University of California Medical Center, San Diego, CA Intern in Medicine Professional Credentials: 10/2009-Present Board Certified: American Board of Dermatology 9/2009-Present Staff Privileges – Veterans Affairs Medical Center, San Diego, CA 7/2009 -Present Staff Privileges – UCSD Medical Center, San Diego, CA 2008 California Medical Licensure: #A100212 2005 Medical Doctor, University of Washington Academic Honors and Awards: 2009 Recipient of Dermatology Foundation (DF) Clinical Symposia Educational Grant 1999-2002 Recipient of ARCS Fellowship 1997-2000 Recipient of Poncin Fellowship 1993 Departmental Distinction, Chemistry, Carleton College 1993 B.A. in Chemistry (Magna Cum Laude) 1993 Distinction in Senior Comprehensive Exercise 1992 Mayo Clinic Undergraduatate Research Fellowship 1990 Recipient of NIH-REU Grant Sigma Xi honor society Mortar Board honor society Professional Societies: 2009-Present Fellow, American Academy of Dermatology 2009-Present Member, Pacific Dermatologic Association Research: Principal Investigator Oct 2012 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Purified Live Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects June 2012 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating the Safety and Efficacy of a β2-Adrenergic Receptor Agonist in the Aesthetic Treatment of Disproportionate Abdominal Bulging Due to Excess Subcutaneous Fat in Healthy, Non-Obese Subjects April 2012 A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Novel Tetracycline, Compared to Placebo in Treatment of Facial Acne Vulgaris Feb 2012 A Phase II Study of Photodynamic Therapy with Aminolevulinic Acid Topical Solution + Blue Light versus a Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face or Scalp Jan 2012 An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Corticosteroid Foam in Subjects with Plaque Psoriasis Receiving Two Weeks of Treatment Nov 2011 A Phase 3 randomized, double-blind, 12-week vehicle-controlled, parallelgroup study assessing the efficacy and safety of a macrocyclic lactone cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40-week investigator-blinded extension comparing the long-term safety of a macrocyclic lactone cream versus azelaic acid 15% gel. Oct 2011 A Phase II Study of Photodynamic Therapy with Aminolevulinic Acid Topical Solution + Blue Light Versus a Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities May 2011 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Rosacea-Related Inflammatory Biochemical Markers in the Skin of Adults with Papulopustular Rosacea Treated with Doxycycline Mar 2011* Efficacy and Safety of an Oral Retinoid in the Treatment of Severe Chronic Hand Dermatitis Refractory to Topical Therapy Feb 2011* A Multicenter, Open Registry of Patients with Psoriasis Who are Candidates for Systemic Therapy Including Biologics Feb 2011* Post-Approval Study of an Approved Dermal Filler for Correction of Nasolabial Folds Feb 2011* A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of an Antifungal Topical Solution versus Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails Feb 2011* A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients with Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of a Novel, Epicutaneously Applied Carrier-Based Dose Form of Terbinafine for 48 Weeks Feb 2011* A Comparative Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion 0.05% versus Halobetasol Propionate Cream 0.05% in Subjects with Moderate to Severe Plaque Psoriasis Receiving Two Weeks of Treatment Feb 2011* A Multicenter, Randomized, Vehicle-controlled, Double-blind, Parallel group Study of Efficacy and Safety of a Vitamin D Derivative Topical Aerosol Applied Twice Daily for 8 Weeks in Subjects with Plaque-type Psoriasis May 2010 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis and Previously Treated with Biologic Anti-TNFα Agents May 2010 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of a Newly Synthesized JAK inhibitor in Subjects with Moderate to Severe Plaque Psoriasis Apr 2010 A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, versus Vehicle Foam in the Treatment of Moderate Plaque-Type Scalp and Body Psoriasis * Assumed responsibility as Principal Investigator Sub-Investigator Dec 2013 Safety and Efficacy of a Synthetic Prostaglandin Versus Vehicle in Men with Androgenic Alopecia Nov 2013 A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of an Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis Oct 2013 A Double-Blind, Randomized, Placebo-Controlled Study to Determine Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of an Alkaline Earth Metal Cream in Healthy Volunteers Sep 2013 A Safety and Efficacy Study to Compare a Synthetic Sulfone Gel with Vehicle Control in Patients with Acne Vulgaris Jul 2013 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of a Humanized Immunoglobulin Monoclonal Antibody to Etanercept and Placebo in Patients with Moderateto-Severe Plaque Psoriasis Jul 2013 A Randomized, Vehicle-Controlled, Double-Blind Parallel Group, MultiCenter Phase III Study to Evaluate the Safety and Efficacy of a Novel Vitamin D3 Analog in Subjects with Plaque Psoriasis Dec 2012 A multicenter, double-blind, randomized withdrawal extension study of subcutaneous fully human monoclonal anti-human interleukin-17A antibody in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding phase III studies with subcutaneous fully human monoclonal anti-human interleukin-17A antibody. Dec 2012 Potent α1a-Adrenergic Receptor Agonist Cream for the Treatment of Erythema Associated with Rosacea Nov 2012 A Multicenter Randomized Evaluator-Blinded, Vehicle Controlled Parallel Group Evaluation of Twice Daily Sodium Sulfacetamide and Sulfur in Comparison to its Monads in Adults with Rosacea Oct 2012 A Randomized, Single-Center, Double-Blind, Parallel-Group Evaluation of Skin Cleansing Using a Surfactant Solution in Comparison to a Vehicle Control in the Appearance of Seborrheic Keratosis and Solar Lentigo Aug 2012 A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of a Human anti-IL-17RA Monoclonal Antibody Compared with Placebo and a Human IgG1K Monoclonal Antibody in Subjects with Moderate to Severe Plaque Psoriasis Aug 2012 A Single-Point, Randomized, Evaluator Blinded, within Subject, Single Center Evaluation of the Vasoconstrictive Properties of Two Topical Corticosteroid Formulations in Healthy Volunteers May 2012 A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of a Topical Corticosteroid Formulation in Subjects with Plaque Psoriasis Receiving Two Weeks of Treatment May 2012 Exploratory Trial to Evaluate the Safety and Efficacy of Two Different Concentrations of a New Chemical Entity in Subjects with Acne Vulgaris May 2012 A Single-Point, Randomized, Evaluator Blinded, Within Subject, Single Center Evaluation of the Vasoconstrictive Properties of a Mid-Potentcy Synthetic Corticosteroid 0.07% and 0.1% Foam Formulations in Healthy Volunteers May 2012 Exploratory Trial to Evaluate the Safety and Efficacy of Two Different Concentrations of Salicylic Acid Derivatives in Subjects with Acne Vulgaris Apr 2012 A Double-Blind Study to Determine and Compare the Cosmetic Attributes of Two Foam Vehicle Formulations in Subjects with Plaque Psoriasis April 2012 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of a Steroidal Antiandrogen Cream Applied Once or Twice-Daily for 12 Weeks in Subjects with Facial Acne Vulgaris Feb 2012 Observational Study of the Use of a Uric Acid-Specific Enzyme in Adult Hyperuricemic Patients with Gout Refractory to Conventional Therapy Feb 2012 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 Weeks Total) of a Human Monoclonal Antibody of Immunoglobulin G1 Class in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease Feb 2012 Observational Study of the Use of a Uric Acid-Specific Enzyme in Adult Hyperuricemic Patients with Gout Refractory to Conventional Therapy Dec 2011 A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Subcutaneous Fully Human Monoclonal Anti-Human Interleukin-17A Antibody to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis Nov 2011 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Recombinant Humanized mAb in Subjects with Moderate to Severe Acne Vulgaris Nov 2011 A Double-Blind, Randomized, Multicenter, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of a Corticosteroid Lotion in Subjects with Plaque Psoriasis Receiving Two Weeks of Treatment Sep 2011 A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of a Synthetic Prostaglandin Solution Compared with Vehicle in Women with Female Pattern Hair Loss with an Open-Label Active Comparator Group Aug 2011 A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of a Synthetic Prostaglandin Solution Compared with Vehicle in Men with Androgenic Alopecia with an Open-Label Active Comparator Group Aug 2011 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of an Oxaborole Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Aug 2011 A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose Ranging Study of the Safety and Efficacy of a Synthetic Trifluorinated Gluticocortoid and a β2-Adrenergic Receptor Agonist in Healthy Patients with Abdominal Contour Defects Aug 2011 An Open-Label, Maximal Use, Systemic Exposure Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Novel Oxaborole Compound in Subjects with Plaque-Type Psoriasis Jul 2011 A First-in-Human Study to Evaluate the Safety and Tolerability of Repeated Topical Administrations of a Klk7 Inhibitor Ointment in Healthy Volunteers, and Safety, Tolerability, and Preliminary Efficacy of Multiple Topical Administrations of a Klk7 Inhibitor in Patients with Atopic Dermatitis and Netherton Syndrome Mar 2011 A Randomized, Vehicle-Controlled, double-blind, parallel group, multicenter phase IIb dose finding study of a vitamin D3 analogue in plaque psoriasis patients Feb 2011 A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Multicenter Study of Subcutaneous Fully Human Monoclonal Anti-Human Interleukin-17A Antibody to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-Term Efficacy Up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis. Feb 2011 A Pivotal USA Randomized, Evaluator-Blinded, Active-Controlled, MultiCenter Split-Face Comparison Study of a Hyaluronic Acid Filler with Lidocaine versus Juvederm® Ultra in the Treatment of Moderate to Severe Facial Wrinkles and Folds Feb 2011 A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects with Moderate to Sever plaque Psoriasis Feb 2011 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Pharmacodynamic Profile of an α1 Agonist Cream in Subjects with Erythematous Rosacea Dec 2010 An Open-Label Study to Assess the Pahramcokinetics with Maximal Use of a New Imidazole Antimycotic Drug in Patients with Moderate to Severe Tinea Pedis or Tinea Cruris Nov 2010 A Multicenter, Randomized, Vehicle-controlled, Double-blind, Parallel group Study of Efficacy and Safety of a Vitamin D Derivative Topical Aerosol Applied Twice Daily for 8 Weeks in Subjects with Plaque-type Psoriasis Nov 2010 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Oct 2010 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, ParallelGroup, Single Treatment Cycle Study of Botulinum Toxin Type A Purified Neurotoxin Complex in Subjects with Lateral Canthal Rhytides Aug 2010 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of an α1 Agonist Cream in Subjects with Erythematous Rosacea Aug 2010 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for theTreatment of Female Pattern Hair Loss (Androgenic Alopecia) Aug 2010 A 12-week Post-treatment, Non-interventional, Observational Study Evaluating the Safety and Duration of Effect of Gluticasone Propionate and Salmeterol Xinafoate for Subcutaneous Injection for the Reduction of Subcutaneous Abdominal Adiposity Aug 2010 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients with Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of a Novel, Epicutaneously Applied Carrier-Based Dose Form of Terbinafine for 48 Weeks Jul 2010 Phase 1b, Open Lable, Dose-Finding Study of Orally Administered Proprietary Mixture of Dietary Fatty Acids in Adults with Atopic Dermatitis Jul 2010 A Comparative Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion 0.05% versus Halobetasol Propionate Cream 0.05% in Subjects with Moderate to Severe Plaque Psoriasis Receiving Two Weeks of Treatment Jun 2010 A Multicenter Extension Trial of Subcutaneously Administered Recombinant, High-Affinity, Fully Human Monoclonal Anti-Human Interleukin-17A Antibody of the IgG1/κ-class in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis Jun 2010 Cognitive Debriefing Interviews to Assess Comprehension and Interpretation of Items Assessing Lateral Canthal Line Appearance May 2010 A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of a Botulinum Toxin Type A Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults May 2010 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis and Previously Treated with Biologic Anti-TNFα Agents Apr 2010 A Blinded, Single Center, Bilateral Comparison Study of Analgesic Effect Following Topical Application of 4% Lidocaine Cream or Placebo After Pretreatment with a Skin Ablation Device versus a Sham Control Device Feb 2010 A Multicenter, Double-Masked, Randomized, Parallel Study Assessing the Safety and Efficacy of Once-daily Application of a Prostaglandin Analog Ophthalmic Solution 0.005% and 0.015% Compared with a Prostaglandin Analog Ophthalmic Solution 0.03% in Increasing Eyelash Prominence. Jan 2010 A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Antifungal Micro Implant Administered Subungually or Distally in the Treatment of Distal Subungual Onychomycosis of the Toenail Dec 2009 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of an Antifungal Topical Solution versus Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails Sep 2009 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to a TNF Inhibitor in Subjects with Moderate to Severe Plaque Psoriasis Sep 2009 An Open-label, Multi-center, Randomized, Evaluator-Blinded Study to Evaluate the Safety and Efficacy of Two Treatment Regimens involving Calcitriol Ointment 3µ/g and Clobetasol Propionate Spray, 0.05% in the Treatment of Moderate Plaque Psoriasis Sep 2009 A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Sep 2009 Bioequivalence Study of a Retinoid Gel, a Marketed Product and Placebo Sep 2009 A Single Center Study of the Pharmacokinetics of Carbazole in Subjects with Mild to Moderate Plaque Psoriasis Treated with Topical Coal Tar Ointment Jul 2009 A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of a Calcineurin Inhibitor Ophthalmic Solution 0.010% compared with Its Vehicle Administered QID for 3 Months Followed by a 9 Month Open-Label Phase in Patients with Atopic Keratoconjunctivitis Jul 2009 A Randomized, Double-Blind, Placebo Controlled, Multicenter Regiment Finding Study of Subcutaneously Administered Antibody to IL-17, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis. May 2009 A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of a Prostaglandin Analogue in Adults with a Diagnosis of Atopic Dermatitis (AD) with Moderate to Very Severe Pruritus Mar 2009 A Prospective, Multi-center, Randomized, Controlled Clinical Investigation of a Tissue-Engineered Dermal Substitute in Subjects with Venous Leg Ulcers Publications: Schmieder GJ, Huang EY, Jarratt M. A Multicenter, Randomized, Vehicle-Controlled Phase 2 Study of Blue Light Photodynamic Therapy (PDT) with Aminolevulinic Acid HCl (ALA) 20% Topical Solution for the Treatment of Actinic Keratoses (AKs) on the Upper Extremities: The Effect of Occlusion During the Drug Incubation Period. Submitted to J Drugs Dermatol – in press. Mousette A, Kum J, Hata T, Huang EY. 2009. Scabies pathologically mimicking bullous pemphigoid. Arch Dermatol. (In Preparation – Presented at PDA 2009) Huang EY, Li W, Loretz C, Perkins JD, Kuhr CS. 2003. Lymphocyte specific expression of Notch1 prolongs survival of heart grafts in an allogeneic murine adoptive transfer model. American Transplant Congress Meeting [Abstract] May 2003. Huang EY, Gallegos AM, Richards SM, Lehar SM, Bevan, MJ. 2003. Surface expression of Notch1 on thymocytes: correlation with the double-negative to doublepositive transition. J Immunol. 171(5):2296-304. Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. 2000. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity.13(1):73-84. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. 1996. The axisinducing activity, stability , and subcellular distribution of b-catenin is regulated in Xenopus embryos by glycogen synthase kinase. Genes and Devel. 10:1443-1454. Friedman DB, Sundberg HA, Huang EY, Davis TN. 1996. The 110-kd spindle pole body component of Saccharomyces cerevisiae is a phosphoprotein that is modifiedin a cell-cycle dependent manner. J Cell Biol. 132:903-914. Maki SL, Huang EY, Reck-Peterson SL, Singer SR. 1995. The terminal meristem of the determinate (det) mutant of Pisum sativum develops as an axillary inflorescence meristem.

What Patients are Saying

18165
Patients treated
50
US States
229
Active Doctors
1h 46m
Avg Response Time

How it Works


smartphone

Connect with your doctor securely from your smartphone, tablet or computer.

questionaire

Fill out a short questionnaire and snap photos of your condition.

diagnosis

Get a personalized treatment plan. Prescriptions are digitally routed to your preferred pharmacy.